Development of vaccination strategies to elicit broadly protective immunity against influenza

制定疫苗接种策略以引发针对流感的广泛保护性免疫力

基本信息

  • 批准号:
    10620353
  • 负责人:
  • 金额:
    $ 84.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-06-18 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT The most effective measure for the prevention of influenza virus infection is vaccination. However, due to ongoing antigenic drift, current influenza vaccines need annual reformulation to provide sufficient protection. Furthermore, immune responses elicited upon influenza vaccination are strain-specific and fail to provide protection against novel seasonal and pandemic viruses, necessitating the development of a universal influenza vaccine with the capacity to elicit lifelong protection against diverse influenza virus strains. A major target for the development of protective immunity against influenza is the hemagglutinin glycoprotein (HA), which comprises two distinct functional domains: the globular head, which participates in viral entry and is subject to antigenic drift, and the stalk domain, which is highly conserved and mediates viral fusion. Immunodominant antigenic sites on the HA head elicit high-affinity, strain-specific anti-HA Ab responses, whereas in contrast, Abs against conserved epitopes can mediate broadly protective activity, but are immunosubdominant. To overcome the inherent immunodominance of the HA head and refocus immunity towards conserved, cross-protective epitopes, we will engineer innovative mosaic HA protein immunogens in which HA head antigenic sites will be silenced. Our prior research demonstrated that vaccination with HA:anti-HA IgG immune complexes (ICs) can modulate adaptive immunity through specific interactions of the Fc domain of the IgG with Fcγ receptors (FcγR) on the surface of effector leukocytes. Our in-depth studies revealed that engagement of specific FcγRs: CD23 on B-cells and FcγRIIa on dendritic cells (DCs), is critical for the induction of high-affinity IgG responses and T-cell immunity, respectively. Based on this knowledge, we will exploit these pathways to broaden specificity, increase affinity and select for long-lived humoral and cellular immunity to conserved influenza epitopes. We will design and evaluate the immunogenicity of IC-based immunogens comprising mosaic HAs and Fc-engineered anti-HA IgGs with selective affinity for specific human FcγR types. These studies will lead to the development and pre-clinical evaluation of vaccination strategies to elicit robust and long-lasting antiviral immunity, which could improve the breadth of current seasonal vaccines, but could also be employed in the development of novel, next-generation universal influenza virus vaccines.
摘要 预防流感病毒感染最有效的措施是接种疫苗。然而,由于正在进行的 抗原性漂移,目前的流感疫苗需要每年重新配制才能提供足够的保护。此外, 接种流感疫苗后产生的免疫反应是针对不同毒株的,因此不能预防流感 新的季节性和大流行病毒,需要开发一种具有通用性的流感疫苗 获得针对不同流感病毒株的终身保护的能力。发展的主要目标是 对流感的保护性免疫是血凝素糖蛋白(HA),它由两种不同的 功能区:参与病毒进入并受抗原漂移影响的球形头部,以及 茎结构域,高度保守,介导病毒融合。HA上的免疫优势抗原部位 Head能诱导高亲和力、菌株特异性的抗HA抗体反应,而与之相反,抗HA抗体 表位可以介导广泛的保护活性,但是免疫亚显性的。克服固有的 HA头部的免疫优势,并将免疫重新聚焦于保守的、交叉保护的表位,我们将 设计创新的马赛克HA蛋白免疫原,其中HA头部抗原位点将被沉默。我们的前辈 研究表明,接种HA:抗HA免疫复合物(ICs)可调节适应性 免疫球蛋白Fc结构域与γ表面Fc受体(FcγR)的特异性相互作用 效应器白细胞。我们的深入研究表明,特定的Fc-γ受体:CD23与B细胞和 FcγRIIA对树突状细胞(DC)的作用,对于诱导高亲和力Ig G反应和T细胞免疫至关重要。 分别进行了分析。基于这些知识,我们将利用这些途径来扩大特异性,增加亲和力 并选择对保守的流感表位进行长寿体液和细胞免疫。我们将设计和 嵌合型HAS和Fc基因工程抗HA免疫原的免疫原性评价 对特定的人FcγR类型具有选择性亲和力。这些研究将导致开发和临床前 评估疫苗接种策略以获得强大和持久的抗病毒免疫,这可能会改善 目前季节性疫苗的广度,但也可以用于开发新的下一代疫苗 通用流感病毒疫苗。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice.
  • DOI:
    10.3389/fimmu.2021.746447
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
    Liu Y;Strohmeier S;González-Domínguez I;Tan J;Simon V;Krammer F;García-Sastre A;Palese P;Sun W
  • 通讯作者:
    Sun W
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
表达SARS-COV-2尖峰的基于鸡蛋的灭活纽卡斯尔病毒疫苗的安全性和免疫原性:越南随机,安慰剂对照,1/2期试验的临时结果。
  • DOI:
    10.1016/j.vaccine.2022.04.078
  • 发表时间:
    2022-06-09
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Anh Duc Dang;Thiem Dinh Vu;Ha Hai Vu;Van Thanh Ta;Anh Thi Van Pham;Mai Thi Ngoc Dang;Be Van Le;Thai Huu Duong;Duoc Van Nguyen;Lawpoolsri, Saranath;Chinwangso, Pailinrut;McLellan, Jason S.;Hsieh, Ching-Lin;Garcia-Sastre, Adolfo;Palese, Peter;Sun, Weina;Martinez, Jose L.;Gonzalez-Dominguez, Irene;Slamanig, Stefan;Carreno, Juan Manuel;Tcheou, Johnstone;Krammer, Florian;Raskin, Ariel;Huong Minh Vu;Thang Cong Tran;Huong Mai Nguyen;Mercer, Laina D.;Raghunandan, Rama;Lal, Manjari;White, Jessica A.;Hjorth, Richard;Innis, Bruce L.;Scharf, Rami
  • 通讯作者:
    Scharf, Rami
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
  • DOI:
    10.1126/scitranslmed.ade4790
  • 发表时间:
    2023-04-19
  • 期刊:
  • 影响因子:
    17.1
  • 作者:
    Widge, Alicia T.;Hofstetter, Amelia R.;V. Houser, Katherine;Awan, Seemal F.;Chen, Grace L.;Florez, Maria C. Burgos;Berkowitz, Nina M.;Mendoza, Floreliz;Hendel, Cynthia S.;Holman, LaSonji A.;Gordon, Ingelise J.;Apte, Preeti;Liang, C. Jason;Gaudinski, Martin R.;Coates, Emily E.;Strom, Larisa;Wycuff, Diane;Vazquez, Sandra;Stein, Judy A.;Gall, Jason G.;Adams, William C.;Carlton, Kevin;Gillespie, Rebecca A.;Creanga, Adrian;Crank, Michelle C.;Andrews, Sarah F.;Castro, Mike;Serebryannyy, Leonid A.;Narpala, Sandeep R.;Hatcher, Christian;Lin, Bob C.;O'Connell, Sarah;Freyn, Alec W.;Rosado, Victoria C.;Nachbagauer, Raffael;Palese, Peter;Kanekiyo, Masaru;McDermott, Adrian B.;Koup, Richard A.;Dropulic, Lesia K.;Graham, Barney S.;Mascola, John R.;Ledgerwood, Julie E.
  • 通讯作者:
    Ledgerwood, Julie E.
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
  • DOI:
    10.1038/s41591-021-01660-8
  • 发表时间:
    2022-02
  • 期刊:
  • 影响因子:
    82.9
  • 作者:
    Houser, Katherine, V;Chen, Grace L.;Carter, Cristina;Crank, Michelle C.;Nguyen, Thuy A.;Florez, Maria Claudia Burgos;Berkowitz, Nina M.;Mendoza, Floreliz;Hendel, Cynthia Starr;Gordon, Ingelise J.;Coates, Emily E.;Vazquez, Sandra;Stein, Judy;Case, Christopher L.;Lawlor, Heather;Carlton, Kevin;Gaudinski, Martin R.;Strom, Larisa;Hofstetter, Amelia R.;Liang, C. Jason;Narpala, Sandeep;Hatcher, Christian;Gillespie, Rebecca A.;Creanga, Adrian;Kanekiyo, Masaru;Raab, Julie E.;Andrews, Sarah F.;Zhang, Yi;Yang, Eun Sung;Wang, Lingshu;Leung, Kwanyee;Kong, Wing-Pui;Freyn, Alec W.;Nachbagauer, Raffael;Palese, Peter;Bailer, Robert T.;McDermott, Adrian B.;Koup, Richard A.;Gall, Jason G.;Arnold, Frank;Mascola, John R.;Graham, Barney S.;Ledgerwood, Julie E.
  • 通讯作者:
    Ledgerwood, Julie E.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter Palese其他文献

Peter Palese的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter Palese', 18)}}的其他基金

Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection
FcgR 抗体依赖性增强 SARS-CoV-2 感染机制的评估
  • 批准号:
    10202128
  • 财政年份:
    2020
  • 资助金额:
    $ 84.75万
  • 项目类别:
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection
FcgR 抗体依赖性增强 SARS-CoV-2 感染机制的评估
  • 批准号:
    10265733
  • 财政年份:
    2020
  • 资助金额:
    $ 84.75万
  • 项目类别:
Development of vaccination strategies to elicit broadly protective immunity against influenza
制定疫苗接种策略以引发针对流感的广泛保护性免疫力
  • 批准号:
    10404020
  • 财政年份:
    2019
  • 资助金额:
    $ 84.75万
  • 项目类别:
Development of vaccination strategies to elicit broadly protective immunity against influenza
制定疫苗接种策略以引发针对流感的广泛保护性免疫力
  • 批准号:
    9796595
  • 财政年份:
    2019
  • 资助金额:
    $ 84.75万
  • 项目类别:
Training Program in Mechanisms of Virus-Host Interactions
病毒-宿​​主相互作用机制培训项目
  • 批准号:
    9390543
  • 财政年份:
    2016
  • 资助金额:
    $ 84.75万
  • 项目类别:
Mechanisms of broadly neutralizing humoral immunity against influenza viruses
广泛中和流感病毒体液免疫的机制
  • 批准号:
    8653053
  • 财政年份:
    2014
  • 资助金额:
    $ 84.75万
  • 项目类别:
Mechanisms of broadly neutralizing humoral immunity against influenza viruses
广泛中和流感病毒体液免疫的机制
  • 批准号:
    8825401
  • 财政年份:
    2014
  • 资助金额:
    $ 84.75万
  • 项目类别:
Mechanisms of broadly neutralizing humoral immunity against influenza viruses
广泛中和流感病毒体液免疫的机制
  • 批准号:
    9040868
  • 财政年份:
    2014
  • 资助金额:
    $ 84.75万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10468073
  • 财政年份:
    2012
  • 资助金额:
    $ 84.75万
  • 项目类别:
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses
优化新型免疫原设计以引发针对流感病毒的广泛保护性免疫反应
  • 批准号:
    10468075
  • 财政年份:
    2012
  • 资助金额:
    $ 84.75万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 84.75万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 84.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了